Galecto, Inc. (GLTO)

Galecto, Inc. (GLTO) stock has experienced significant volatility and notable events in the past six months. Galecto completed the acquisition of Damora Therapeutics on November 10, 2025, supported by a $284.9 million private placement, leading to a substantial increase in its stock price. GLTO stock has seen a significant rise of 441.74% over the last six months, with a stock price of $17.39 as of November 27, 2025. Galecto shares underwent a 1-for-25 reverse stock split on August 30, 2024. The company reported a net loss of $3.1 million in the third quarter of 2025 and had a cash position of $11.9 million as of March 31, 2025.

Information regarding demand seasonality for Galecto, Inc.'s specific products and services is not available. As a clinical-stage biotechnology company, its revenue generation primarily comes from strategic collaborations and licensing agreements, rather than direct product sales. Therefore, traditional demand seasonality is unlikely to be a significant factor for Galecto.

Galecto, Inc. is a clinical-stage biotechnology company focused on developing small molecule therapeutics for cancer and severe liver diseases, targeting galectin-3, LOXL2, ENL-YEATS, and FLT3 proteins. The company operates in the Healthcare sector, specifically in the Biotechnology and Pharmaceutical Preparations industry. Its major product candidates include GB0139 for severe fibrotic lung diseases, GB1211 for fibrosis related to NASH, NSCLC, melanoma, HNSCC, and decompensated cirrhosis, GB2064 for myelofibrosis, and GB3226 for multiple genetic subsets of AML.

Galecto, Inc. was founded in 2011 and is headquartered in Boston, Massachusetts, with an original location in Copenhagen, Denmark.

Galecto's brand reputation has been influenced by its strategic developments and stock performance. The acquisition of Damora Therapeutics and subsequent funding likely boosted its reputation. However, the company faces inherent risks related to clinical trial outcomes and regulatory approvals. Analyst sentiment indicates a "Sell" consensus rating, suggesting a cautious view regarding its market position and future outlook.

Galecto, Inc. is owned by a mix of institutional shareholders, insiders, and the general public. Approximately 12.82% to 14.20% of Galecto's stock is held by institutional investors, including Novo Holdings A/S and Connective Capital Management, LLC. Galecto insiders hold a significant portion, around 504.69%, with Orbimed Advisors LLC being the largest individual shareholder. The general public owns approximately 78.2% of Galecto's shares.